BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 35489428)

  • 1. β-Catenin Sustains and Is Required for YES-associated Protein Oncogenic Activity in Cholangiocarcinoma.
    Zhang Y; Xu H; Cui G; Liang B; Chen X; Ko S; Affo S; Song X; Liao Y; Feng J; Wang P; Wang H; Xu M; Wang J; Pes GM; Ribback S; Zeng Y; Singhi A; Schwabe RF; Monga SP; Evert M; Tang L; Calvisi DF; Chen X
    Gastroenterology; 2022 Aug; 163(2):481-494. PubMed ID: 35489428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Hippo pathway effector TAZ induces intrahepatic cholangiocarcinoma in mice and is ubiquitously activated in the human disease.
    Cigliano A; Zhang S; Ribback S; Steinmann S; Sini M; Ament CE; Utpatel K; Song X; Wang J; Pilo MG; Berger F; Wang H; Tao J; Li X; Pes GM; Mancarella S; Giannelli G; Dombrowski F; Evert M; Calvisi DF; Chen X; Evert K
    J Exp Clin Cancer Res; 2022 Jun; 41(1):192. PubMed ID: 35655220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of Fbxw7 synergizes with activated Akt signaling to promote c-Myc dependent cholangiocarcinogenesis.
    Wang J; Wang H; Peters M; Ding N; Ribback S; Utpatel K; Cigliano A; Dombrowski F; Xu M; Chen X; Song X; Che L; Evert M; Cossu A; Gordan J; Zeng Y; Chen X; Calvisi DF
    J Hepatol; 2019 Oct; 71(4):742-752. PubMed ID: 31195063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of β-catenin and Yap1 in human hepatoblastoma and induction of hepatocarcinogenesis in mice.
    Tao J; Calvisi DF; Ranganathan S; Cigliano A; Zhou L; Singh S; Jiang L; Fan B; Terracciano L; Armeanu-Ebinger S; Ribback S; Dombrowski F; Evert M; Chen X; Monga SPS
    Gastroenterology; 2014 Sep; 147(3):690-701. PubMed ID: 24837480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Co-expression of YAP and TAZ associates with chromosomal instability in human cholangiocarcinoma.
    Tóth M; Wehling L; Thiess L; Rose F; Schmitt J; Weiler SME; Sticht C; De La Torre C; Rausch M; Albrecht T; Grabe N; Duwe L; Andersen JB; Köhler BC; Springfeld C; Mehrabi A; Kulu Y; Schirmacher P; Roessler S; Goeppert B; Breuhahn K
    BMC Cancer; 2021 Oct; 21(1):1079. PubMed ID: 34615513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. YAP Accelerates Notch-Driven Cholangiocarcinogenesis via mTORC1 in Mice.
    Lu X; Peng B; Chen G; Pes MG; Ribback S; Ament C; Xu H; Pal R; Rodrigues PM; Banales JM; Evert M; Calvisi DF; Chen X; Fan B; Wang J
    Am J Pathol; 2021 Sep; 191(9):1651-1667. PubMed ID: 34129844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. YAP1 activation and Hippo pathway signaling in the pathogenesis and treatment of intrahepatic cholangiocarcinoma.
    Ko S; Kim M; Molina L; Sirica AE; Monga SP
    Adv Cancer Res; 2022; 156():283-317. PubMed ID: 35961703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Focal adhesion kinase (FAK) promotes cholangiocarcinoma development and progression via YAP activation.
    Song X; Xu H; Wang P; Wang J; Affo S; Wang H; Xu M; Liang B; Che L; Qiu W; Schwabe RF; Chang TT; Vogl M; Pes GM; Ribback S; Evert M; Chen X; Calvisi DF
    J Hepatol; 2021 Oct; 75(4):888-899. PubMed ID: 34052254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activated TAZ induces liver cancer in collaboration with EGFR/HER2 signaling pathways.
    Moon H; Park H; Chae MJ; Choi HJ; Kim DY; Ro SW
    BMC Cancer; 2022 Apr; 22(1):423. PubMed ID: 35439973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The PDZ-binding motif of Yes-associated protein is required for its co-activation of TEAD-mediated CTGF transcription and oncogenic cell transforming activity.
    Shimomura T; Miyamura N; Hata S; Miura R; Hirayama J; Nishina H
    Biochem Biophys Res Commun; 2014 Jan; 443(3):917-23. PubMed ID: 24380865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NOTCH-YAP1/TEAD-DNMT1 Axis Drives Hepatocyte Reprogramming Into Intrahepatic Cholangiocarcinoma.
    Hu S; Molina L; Tao J; Liu S; Hassan M; Singh S; Poddar M; Bell A; Sia D; Oertel M; Raeman R; Nejak-Bowen K; Singhi A; Luo J; Monga SP; Ko S
    Gastroenterology; 2022 Aug; 163(2):449-465. PubMed ID: 35550144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. WWC1 and NF2 Prevent the Development of Intrahepatic Cholangiocarcinoma by Regulating YAP/TAZ Activity through LATS in Mice.
    Park J; Kim JS; Nahm JH; Kim SK; Lee DH; Lim DS
    Mol Cells; 2020 May; 43(5):491-499. PubMed ID: 32451369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brahma-Related Gene 1 Inhibition Prevents Liver Fibrosis and Cholangiocarcinoma by Attenuating Progenitor Expansion.
    Zhou Y; Chen Y; Zhang X; Xu Q; Wu Z; Cao X; Shao M; Shu Y; Lv T; Lu C; Xie M; Wen T; Yang J; Shi Y; Bu H
    Hepatology; 2021 Aug; 74(2):797-815. PubMed ID: 33650193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Crosslinked Extracellular Matrix Stiffens Human Trabecular Meshwork Cells Via Dysregulating β-catenin and YAP/TAZ Signaling Pathways.
    Yemanyi F; Vranka J; Raghunathan VK
    Invest Ophthalmol Vis Sci; 2020 Aug; 61(10):41. PubMed ID: 32832971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TBX3 functions as a tumor suppressor downstream of activated CTNNB1 mutants during hepatocarcinogenesis.
    Liang B; Zhou Y; Qian M; Xu M; Wang J; Zhang Y; Song X; Wang H; Lin S; Ren C; Monga SP; Wang B; Evert M; Chen Y; Chen X; Huang Z; Calvisi DF; Chen X
    J Hepatol; 2021 Jul; 75(1):120-131. PubMed ID: 33577921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cooperation Between MYC and β-Catenin in Liver Tumorigenesis Requires Yap/Taz.
    Bisso A; Filipuzzi M; Gamarra Figueroa GP; Brumana G; Biagioni F; Doni M; Ceccotti G; Tanaskovic N; Morelli MJ; Pendino V; Chiacchiera F; Pasini D; Olivero D; Campaner S; Sabò A; Amati B
    Hepatology; 2020 Oct; 72(4):1430-1443. PubMed ID: 31965581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of Mothers Against Decapentaplegic Homolog 7 Activates the Yes-Associated Protein/NOTCH Cascade and Promotes Liver Carcinogenesis in Mice and Humans.
    Wang H; Song X; Liao H; Wang P; Zhang Y; Che L; Zhang J; Zhou Y; Cigliano A; Ament C; Superville D; Ribback S; Reeves M; Pes GM; Liang B; Wu H; Evert M; Calvisi DF; Zeng Y; Chen X
    Hepatology; 2021 Jul; 74(1):248-263. PubMed ID: 33368437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma in mice.
    Zhang S; Song X; Cao D; Xu Z; Fan B; Che L; Hu J; Chen B; Dong M; Pilo MG; Cigliano A; Evert K; Ribback S; Dombrowski F; Pascale RM; Cossu A; Vidili G; Porcu A; Simile MM; Pes GM; Giannelli G; Gordan J; Wei L; Evert M; Cong W; Calvisi DF; Chen X
    J Hepatol; 2017 Dec; 67(6):1194-1203. PubMed ID: 28733220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. α-catenin interaction with YAP/FoxM1/TEAD-induced CEP55 supports liver cancer cell migration.
    Tang Y; Thiess L; Weiler SME; Tóth M; Rose F; Merker S; Ruppert T; Schirmacher P; Breuhahn K
    Cell Commun Signal; 2023 Jun; 21(1):162. PubMed ID: 37381005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EIF3H stabilizes CCND1 to promotes intrahepatic cholangiocarcinoma progression via Wnt/β-catenin signaling.
    Wei Y; Chen W; Li Z; Xie K; Liu F
    FASEB J; 2022 Dec; 36(12):e22647. PubMed ID: 36350008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.